Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?
- PMID: 16785477
- DOI: 10.7326/0003-4819-144-12-200606200-00005
Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?
Abstract
Background: Because coronary perfusion occurs mainly during diastole, patients with coronary artery disease (CAD) could be at increased risk for coronary events if diastolic pressure falls below critical levels.
Objective: To determine whether low blood pressure could be associated with excess mortality and morbidity in this population.
Design: A secondary analysis of data from the International Verapamil-Trandolapril Study (INVEST), which was conducted from September 1997 to February 2003.
Setting: 862 sites in 14 countries.
Patients: 22 576 patients with hypertension and CAD.
Interventions: Patients from INVEST were randomly assigned to a verapamil sustained-release- or atenolol-based strategy; blood pressure control and outcomes were equivalent.
Measurements: An unadjusted quadratic proportional hazards model was used to evaluate the relationship between average on-treatment blood pressure and risk for the primary outcome (all-cause death, nonfatal stroke, and nonfatal myocardial infarction [MI]), all-cause death, total MI, and total stroke. A second model adjusted for differences in baseline covariates.
Results: The relationship between blood pressure and the primary outcome, all-cause death, and total MI was J-shaped, particularly for diastolic pressure, with a nadir at 119/84 mm Hg. After adjustment, the J-shaped relationship persisted between diastolic pressure and primary outcome. The MI-stroke ratio remained constant over a wide blood pressure range, but at a lower diastolic blood pressure, there were substantially more MIs than strokes. An interaction between decreased diastolic pressure and history of revascularization was observed; low diastolic pressure was associated with a relatively lower risk for the primary outcome in patients with revascularization than in those without revascularization.
Limitations: This is a post hoc analysis of hypertensive patients with CAD.
Conclusions: The risk for the primary outcome, all-cause death, and MI, but not stroke, progressively increased with low diastolic blood pressure. Excessive reduction in diastolic pressure should be avoided in patients with CAD who are being treated for hypertension.
Trial registration: ClinicalTrials.gov NCT00133692.
Comment in
-
Diastolic blood pressure in coronary artery disease.Ann Intern Med. 2007 Jan 16;146(2):149. doi: 10.7326/0003-4819-146-2-200701160-00016. Ann Intern Med. 2007. PMID: 17227944 No abstract available.
-
Treating high blood pressure in patients with stable coronary artery disease: how low should we go?Curr Cardiol Rep. 2007 Nov;9(6):437-40. doi: 10.1007/BF02938386. Curr Cardiol Rep. 2007. PMID: 17999867 No abstract available.
Similar articles
-
A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.JAMA. 2003 Dec 3;290(21):2805-16. doi: 10.1001/jama.290.21.2805. JAMA. 2003. PMID: 14657064 Clinical Trial.
-
Risk and Blood Pressure Control Rates Across the Spectrum of Coronary Artery Disease in Hypertensive Women: An Analysis from The INternational VErapamil SR-Trandolapril STudy (INVEST).J Womens Health (Larchmt). 2020 Feb;29(2):158-166. doi: 10.1089/jwh.2018.7235. Epub 2019 Aug 12. J Womens Health (Larchmt). 2020. PMID: 31403360
-
Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis.Eur Heart J. 2009 Jun;30(11):1395-401. doi: 10.1093/eurheartj/ehp109. Epub 2009 Apr 7. Eur Heart J. 2009. PMID: 19351690 Clinical Trial.
-
Trandolapril/verapamil sustained release: a review of its use in the treatment of essential hypertension.Drugs. 2005;65(13):1893-914. doi: 10.2165/00003495-200565130-00011. Drugs. 2005. PMID: 16114984 Review.
-
Efficacy of Calcium Channel Blockers Versus Other Classes of Antihypertensive Medication in the Treatment of Hypertensive Patients With Previous Stroke and/or Coronary Artery Disease: A Systematic Review and Meta-Analysis.Am J Ther. 2017 Jan/Feb;24(1):e68-e80. doi: 10.1097/MJT.0000000000000369. Am J Ther. 2017. PMID: 26588586 Review.
Cited by
-
Achievement of guideline-recommended target blood pressure is associated with reducing the risk of hemorrhagic and ischemic stroke in Japanese coronary artery disease patients -the CLIDAS study.Hypertens Res. 2024 Sep 19. doi: 10.1038/s41440-024-01902-5. Online ahead of print. Hypertens Res. 2024. PMID: 39300294
-
Impact of a Precision Intervention for Vascular Health in Middle-Aged and Older Postmenopausal Women Using Polar Heart Rate Sensors: A 24-Week RCT Study Based on the New Compilation of Tai Chi (Bafa Wubu).Sensors (Basel). 2024 Sep 8;24(17):5832. doi: 10.3390/s24175832. Sensors (Basel). 2024. PMID: 39275744 Free PMC article. Clinical Trial.
-
Association of office blood pressure with ischemic and bleeding events in patients undergoing percutaneous coronary intervention.Sci Rep. 2024 Sep 2;14(1):20310. doi: 10.1038/s41598-024-71060-8. Sci Rep. 2024. PMID: 39218965 Free PMC article.
-
Intensive blood pressure control in isolated systolic hypertension: a post hoc analysis of a cluster randomized trial.Lancet Reg Health West Pac. 2024 Jun 28;48:101127. doi: 10.1016/j.lanwpc.2024.101127. eCollection 2024 Jul. Lancet Reg Health West Pac. 2024. PMID: 39040034 Free PMC article.
-
Blood pressure during long-term cilostazol-based dual antiplatelet therapy after stroke: a post hoc analysis of the CSPS.com trial.Hypertens Res. 2024 Sep;47(9):2238-2249. doi: 10.1038/s41440-024-01742-3. Epub 2024 Jul 9. Hypertens Res. 2024. PMID: 38977876 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous